Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS

Douglas L Arnold, Till Sprenger, Amit Bar-Or, Jerry S Wolinsky, Ludwig Kappos, Shannon Kolind, Ulrike Bonati, Stefano Magon, Johan van Beek, Harold Koendgen, Oscar Bortolami, Corrado Bernasconi, Laura Gaetano, Anthony Traboulsee

Open source

DOI: 10.1177/13524585221097561
Published: 2022-06-07
Container: Multiple Sclerosis Journal
Publisher: SAGE Publications
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1177/13524585221097561,
  title = {Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS},
  author = {Douglas L Arnold and Till Sprenger and Amit Bar-Or and Jerry S Wolinsky and Ludwig Kappos and Shannon Kolind and Ulrike Bonati and Stefano Magon and Johan van Beek and Harold Koendgen and Oscar Bortolami and Corrado Bernasconi and Laura Gaetano and Anthony Traboulsee},
  year = {2022},
  journal = {Multiple Sclerosis Journal},
  doi = {10.1177/13524585221097561},
  url = {https://doi.org/10.1177/13524585221097561}
}

RIS

TY  - JOUR
TI  - Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS
AU  - Douglas L Arnold
AU  - Till Sprenger
AU  - Amit Bar-Or
AU  - Jerry S Wolinsky
AU  - Ludwig Kappos
AU  - Shannon Kolind
AU  - Ulrike Bonati
AU  - Stefano Magon
AU  - Johan van Beek
AU  - Harold Koendgen
AU  - Oscar Bortolami
AU  - Corrado Bernasconi
AU  - Laura Gaetano
AU  - Anthony Traboulsee
PY  - 2022
JO  - Multiple Sclerosis Journal
DO  - 10.1177/13524585221097561
UR  - https://doi.org/10.1177/13524585221097561
ER  -

APA

Arnold, D. L., Sprenger, T., Bar-Or, A., Wolinsky, J. S., Kappos, L., Kolind, S., Bonati, U., Magon, S., Beek, J. V., Koendgen, H., Bortolami, O., Bernasconi, C., Gaetano, L., & Traboulsee, A. (2022). Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS. Multiple Sclerosis Journal. https://doi.org/10.1177/13524585221097561

Source records

crossref · retrieved 2026-09-25T18:33:46.935Z